This symposium was funded by Menarini Stemline. This content is intended for healthcare professionals only.
In this ESMO 2025 Industry Satellite Symposium, Peter Schmid and Virginia Kaklamani explored evolving treatment strategies for patients with ER+/HER2− early breast cancer.
They discussed personalising treatment decisions based on individual patient profiles, novel approaches to reduce recurrent risk, and the latest developments transforming the management of early breast cancer.
Chair:
Peter Schmid1
Speaker:
Virginia Kaklamani2
1. Barts Cancer Institute, Queen Mary University of London, United Kingdom
2. The University of Texas Health Science Centre San Antonio, Texas, USA
